2017 CEO Shareholder Letter: Translation from R&D to Stem Cell Therapies Accelerates Revenue and Prospects for Future Growth

Golden, Colorado—December 20, 2017—Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced its CEO letter to its shareholders including discussion of 2016 & 2017 results and plans for 2018 including regenerative medicine initiatives for expanding indications.

Dear Shareholders,

In 2016-2017 we achieved:

Accelerated translation from research products to stem cell therapies.
Expansion of our facility costing $125,000 […]

December 27th, 2017|

Vitro Biopharma Files Patent for its Novel Stem Cell Line with Broad Application to Stem Cell Therapies

Golden, Colorado—November 21, 2017 —Vitro Diagnostics, Inc. (OTCPK: VODG), dba Vitro Biopharma, announced the filing of a USPTO patent application regarding a novel stem cell line and its application to treatment of a variety of conditions including skeletal muscular, neurological, immune system dysfunction and other diseases or injuries as well.  The new stem cell line […]

November 29th, 2017|

Vitro Biopharma Reports Positive Clinical Trial Results of Stem Cell Activation Therapy for Autism

Golden, Colorado—August 8, 2017 —Vitro Diagnostics, Inc. (OTCPK: VODG), dba Vitro Biopharma, announced initial results of a Phase I clinical trial testing the effects of its proprietary stem cell activation compounds for safety and efficacy in autistic patients. Safety was the primary endpoint of our non-randomized, pilot study and our preliminary data […]

August 9th, 2017|

Vitro Biopharma Receives Funding to Expand its Stem Cell Therapies

Golden, Colorado—March 29, 2017 —Vitro Diagnostics, Inc. (OTCPK: VODG), dba Vitro Biopharma, announced the completion of a bridge loan in the amount of $125,000 and the execution of a Memorandum of Understanding (“MOU”) outlining the terms of a larger, subsequent financing to provide a total of not less than $1.7 million.  Completion of the subsequent […]

April 14th, 2017|

Vitro Biopharma Files New Patents for Stem Cell Therapy of Neurological Conditions

Golden, Colorado—November 7, 2016 —Vitro Diagnostics, Inc. (OTCPK: VODG), dba Vitro Biopharma, announced the filing of four new patent applications at the United States Patent Office seeking protection of its proprietary stem cell products and technology related to treatment of neurological conditions.  The new patents cover technology related to activation of stem cells within the […]

November 14th, 2016|

Vitro Biopharma Launches New Products to Advance Breast Cancer Treatment

Golden, Colorado—May 3, 2016 —Vitro Diagnostics, Inc. (OTCPK: VODG), dba Vitro Biopharma, announced the launch of breast cancer CAFs (cancer-associated fibroblasts) that provide additional tools for drug discovery in the quest to eradicate cancer. CAFs reside within tumor tissue and serve various functions including suppression of immune responses to cancerous cells, support of tumor cell growth and enhancement of […]

May 4th, 2016|

Vitro Biopharma Announces Early 2016 Results: Increased Revenue and Expansion Activities to Fuel Growth

Golden, Colorado—March 1, 2016 —Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced increased revenues during its first fiscal quarter 2016 of 143% compared to the same period in 2015, predominately due to further increased sales of its cell lines and MSC-Gro™ Brand of cell culture media products. Vitro Biopharma’s cell line product sales are being driven by […]

March 7th, 2016|

Vitro Biopharma Advances Stem Cell Activation Therapy for Concussion

Golden, Colorado—December 29, 2015 —Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced new developments of its stem cell activation therapy for concussion.  Dr. Omula’s research tying repetitive concussion to chronic traumatic encephalopathy is chronicled in the recently released movie, “Concussion.”  Vitro Biopharma is a leader in the field of stem cell activation therapy now […]

January 12th, 2016|

CEO Letter to Shareholders: 2015 Results Expand Therapy Options for Concussion

Dear Shareholders:

Concussion and traumatic brain injury (TBI) are significant health risks that lack modern therapeutic approaches beyond physical therapy and rehabilitation.  The TBI incidence in the US is 1.5 to 1.7 million new cases per year and is estimated to cost $75 billion per year in the US only.  Concussion is a growing issue within […]

November 5th, 2015|

Vitro Biopharma Launches New Bioanalytical Services and Novel Stem Cell-derived Renal & Neural Cells

Golden, Colorado—September  22, 2015 —Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced expansion of its product/service offerings to include biomarker profiling services and stem cell derived neuronal and renal cells. Vitro Biopharma’s new services include simultaneous determination of several molecules through multi-plexed assays.  The cells of our bodies communicate with each other through the […]

September 25th, 2015|